汉方制药IPO前实控人兄弟拿走2亿元分红，董事长秦文基70岁高龄

Core Viewpoint - Shandong Hanfang Pharmaceutical Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with Zhongtai International as its sole sponsor. The company specializes in the production, sales, and research of traditional Chinese medicine products, focusing on treatments for skin and mucosal diseases [2]. Group 1: Company Overview - Hanfang Pharmaceutical was established in June 2004 and operates as a comprehensive pharmaceutical company engaged in traditional Chinese medicine [2]. - The product portfolio is divided into three main categories: prescription external Chinese medicine, classic formula Chinese medicine products, and cosmetics [2]. - The flagship product, Compound Huangbai Liquid, is the only approved prescription topical Chinese medicine in China and is classified as a national secondary protected Chinese medicine [2]. Group 2: Market Position - According to Frost & Sullivan, Compound Huangbai Liquid ranks fourth in the Chinese and international external Chinese medicine market, holding a market share of 1.1% based on projected sales revenue for 2024 [2]. Group 3: Financial Performance - The revenue for Hanfang Pharmaceutical for the years 2023, 2024, and the first nine months of 2025 is reported as 1.053 billion RMB, 992 million RMB, and 803 million RMB respectively [3][4]. - The profit for the same periods is 237 million RMB, 199 million RMB, and 145 million RMB, with gross profit margins of 84.3%, 82.5%, and 84.3% respectively [3][4]. - The company has also reported other income and gains, sales and marketing expenses, and general and administrative expenses, contributing to its overall financial performance [4]. Group 4: Shareholder Information - The chairman and executive director, Qin Wenji, and his brother, Qin Yingji, hold significant voting rights in the company, with Qin Wenji controlling approximately 90% of the voting rights through 27 million shares [4]. - The dividends declared for 2024 and the first nine months of 2025 are 50 million RMB and 150 million RMB, respectively, with the majority of dividends going to the Qin brothers [6].